4.6 Article

RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma

Journal

CLINICAL AND EXPERIMENTAL MEDICINE
Volume 22, Issue 2, Pages 229-243

Publisher

SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10238-021-00742-8

Keywords

RMI2; Hepatocellular carcinoma; Prognosis; Growth; p53

Funding

  1. National Natural Science Foundation of China [31971166]

Ask authors/readers for more resources

The study found that RMI2 is overexpressed in HCC tissues, correlating with poor prognosis. Overexpression of RMI2 promotes proliferation and inhibits apoptosis of HCC cells, while reducing the protein expression of key effector molecules in the p53 signaling pathway.
Genomic instability is a hallmark of all cancers. RMI2 is a crucial component of the BLM-TopoIIIa-RMI1-RMI2 complex that maintains genome stability. It has been shown to accelerate tumor progression in lung cancer, cervical cancer, and prostate cancer. However, its expression and function in hepatocellular carcinoma (HCC) remain poorly defined. In this study, gene expression data and corresponding clinical information of HCC were downloaded from the TCGA, ICGC, and GEO databases. The expression level and clinical significance of RMI2 in HCC were then analyzed. In addition, cellular and molecular biology experiments were conducted to explore the effects of silencing and overexpression of RMI2 on human liver cancer cells and the associated mechanisms. The results showed that RMI2 expression was elevated in HCC tissues. High expression of RMI2 was correlated with shorter survival and poor prognosis of patients. The results of CCK-8, Edu, and clonogenic assays confirmed that RMI2 overexpression promoted the proliferation of HCC cells. Flow cytometric analysis demonstrated that RMI2 overexpression enhanced G1-S phase transition and decreased apoptosis. Moreover, the protein expression of key effector molecules in the p53 signaling pathway was reduced following RMI2 overexpression. In summary, these results indicate that RMI2 promotes the growth of HCC cells and suppresses their apoptosis by inhibiting the p53 signaling pathway. This study provides new insights into the mechanisms driving HCC tumorigenesis and new therapeutic targets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available